NASDAQ:TLSI TriSalus Life Sciences Q3 2026 Earnings Date & Estimates $3.48 -0.16 (-4.27%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more. TriSalus Life Sciences is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeAfter Market ClosesConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from TriSalus Life Sciences in Q3 2026TriSalus Life Sciences is expected to post earnings of -$0.14 per share on revenue of $14.02 million. In the same quarter a year earlier TriSalus Life Sciences reported -$0.96 per share on revenue of $11.57 million. TriSalus Life Sciences last reported on August 6, 2026, posting -$0.16 per share and missing the -$0.1550 consensus estimate. TriSalus Life Sciences has beaten the consensus EPS estimate in 1 of its last 6 quarters.Consensus EstimatesConsensus EPS-$0.14Expected Revenue$14.02 millionPrior-Year EPS-$0.96Prior-Year Revenue$11.57 millionExpected Revenue Growth+21.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.16 (Missed by -$0.0050)Last Quarter Revenue$11.41 millionEPS Beat Rate1 of last 6 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report TriSalus Life Sciences Q3 2026 Earnings FAQ When does TriSalus Life Sciences report Q3 2026 earnings? TriSalus Life Sciences (NASDAQ:TLSI) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is TriSalus Life Sciences' Q3 2026 earnings call? TriSalus Life Sciences' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for TriSalus Life Sciences? Analysts expect TriSalus Life Sciences to post earnings of -$0.14 per share for Q3 2026. How much revenue is TriSalus Life Sciences expected to report? The consensus revenue estimate for TriSalus Life Sciences is $14.02 million for Q3 2026. TriSalus Life Sciences Earnings HeadlinesTriSalus Life Sciences (NASDAQ:TLSI) Stock Jumps 0.8% - Time to Buy?October 27, 2026 | americanbankingnews.comTriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference CallOctober 20, 2026 | businesswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 3 at 1:00 AM | Porter & Company (Ad)H.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)October 3, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH), TriSalus Life Sciences (TLSI) and Immuneering (IMRX)September 24, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: TriSalus Life Sciences (TLSI) and Eli Lilly & Co (LLY)September 24, 2026 | theglobeandmail.comSee More TriSalus Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TriSalus Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TriSalus Life Sciences and other key companies, straight to your email. Email Address About TriSalus Life SciencesTriSalus Life Sciences (NASDAQ:TLSI) is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches. Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply. TriSalus offers interventional oncology devices, including the TriNav Infusion System, which is designed to support localized delivery of treatments while helping limit drug diversion away from the targeted tumor. TriSalus also develops investigational immunotherapy combinations intended to work with its delivery platform, including programs involving immune checkpoint inhibitors and other cancer treatments. The company’s clinical and commercial activities are primarily focused on oncology care in the United States, with an emphasis on hepatocellular carcinoma, intrahepatic cholangiocarcinoma and metastatic pancreatic cancer.View TriSalus Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings BeatCheck Point's Turnaround Could Be Closer Than Investors ThinkTempus AI Surges on Earnings Beat, But Can the Rally Last? Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
